he is not having a good year i hear, this should stick a fork in the fund now
Conroy may ring the bell a richer man
Moving forward, I have a relatively bullish expectation of what we can expect to see from EXAS. While the company may have missed revenue, I am incredibly excited about the earnings beat. However, my bullish expectations go far beyond the earnings beat. As mentioned by the CEO at Exact Sciences, Cologuard is expected to see sales climb. If things go as projected, we're going to see exponential year over year growth, leading to massive gains in the value of the stock throughout 2016. All in all, I'm expecting to see incredibly positive activity.
Guidance – While earnings and revenue were a wash, what has me excited about the stock is the guidance. EXAS is expecting that it will be completing more than 240,000 Cologuard tests throughout the year 2016. If this is indeed the case, the company will generate between $90 and $100 million in revenue in the year 2016. This will prove to be year over year growth in the amount of about 130%. Which would be an impressive feat for any company.
Exact Sciences Corp. saw a surge in revenue for the fourth quarter and for the full year of 2015 as use of the company’s noninvasive colorectal cancer screening test ramps up.
Officials with the Madison-based biotechnology firm are projecting that use of its Cologuard product will more than double in 2016.